Key facts
- Ribocure Pharmaceuticals’s last known valuation is $102.0M (Jul 2025).
- It has raised $33.0M; the latest was Angel (individual) ($33.0M) in Jul 2025.
- Notable investors include Erik Selin, Jacob Torell.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ribocure Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Ribocure Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ribocure Pharmaceuticals
Developer of oligonucleotide therapeutics designed to address the significant medical gaps in rare diseases involved in the fields of cardiovascular, renal and oncology. The company designs and develops drug assets utilizing advanced oligonucleotide technologies and encompasses the entire process from sequence design, screening and optimization to delivery technologies and large-scale commercial CMC capacity, enabling healthcare professionals to conduct research studies of good quality and contribute to bringing new treatments to patients.
- Sector
- Healthcare
- HQ
- Mölndal, Sweden
- Founded
- 2022
- Employees
- 50
- Website
- ribocure.com/
- Ownership
- Privately Held (backing)
Ribocure Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ribocure Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ribocure Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.